SV

Street Verdict

Analyst Scorecard

A record of what Kotak Institutional Equities Analysis said publicly, with the source. Not advice.

“Kotak Equities expects Dr. Reddy's North America base business (ex-Revlimid) sales to decline 4% QoQ to $303 million due to market share loss in certain molecules. However, they factor in higher gRevlimid sales of $145 million in 3QFY25, up from $130 million in 2QFY25. Overall, they project DRRD's sales to grow 13% YoY (+1% QoQ) in 3QFY25, driven by 14% YoY growth in domestic sales and contributions from in-licensing deals.”

Kotak Institutional Equities Analysis’s track record (trackable calls only): 40 graded calls · 95% CI 29–58%

Dr. Reddy's Laboratories LimitedBullishCalled 22 Jan 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Kotak Institutional Equities Analysis’s full track record